In this article, we aimed to characterize the effects of three inhibitors of the PI3K/AKT/mTOR pathway (TAK‐228, everolimus and TAK‐117) on the regulation and function of the PD‐1/PD‐L1 pathway in BC models and to explore whether the effects of the mTOR pathway inhibition in cancer cells may affect the anti‐tumor immune responses. Here, MTOR is linked to breast cancer.